Trimethoprim-sulfamethoxazole (SXT) is the preferable treatment option of the infections caused by Achromobacter spp. Our study aimed to analyze the SXT resistance of 98 Achromobacter spp. isolates from pediatric patients, among which 33 isolates were SXT-resistant. The presence of intI1 was screened by PCR and genome sequence analyses. The intI1 gene was detected in 10 of SXT-resistant isolates that had shorter intI1 PCR fragments named intI1S. Structural changes in intI1S were confirmed by genome sequencing and analyses which revealed 86 amino acids deletion in IntI1S protein compared to canonical IntI1 protein. All IntI1S isolates were of non-CF origin. Pan-genome analysis of intI1S bearing A. xylosoxidans isolates comprised 9052 genes, with the core genome consisting of 5455 protein-coding genes. Results in this study indicate that IntI1S isolates were derived from clinical settings and that cystic fibrosis (CF) patients were potential reservoirs for healthcare-associated infections that occurred in non-CF patients.

• MeSH
• Achromobacter denitrificans * genetika   MeSH
• Achromobacter * MeSH
• antibakteriální látky terapeutické užití   MeSH
• cystická fibróza * MeSH
• dítě MeSH
• genomika MeSH
• gramnegativní bakteriální infekce * MeSH
• integrasy terapeutické užití   MeSH
• integrony genetika   MeSH
• kombinace léků trimethoprim a sulfamethoxazol MeSH
• lidé MeSH
• mikrobiální testy citlivosti MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Srbsko MeSH